Citigroup
HAE icon

Citigroup’s Haemonetics HAE Stock Holding History

Citigroup’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-220,000
Closed -$17.6M – 6127
2025
Q4 		$17.6M Buy
+220,000
New +$14.8M 0.01% 1186

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citigroup's HAE Position: Q1 2026 in Review

Citigroup reduced its Haemonetics (HAE) stake by 56% in Q1 2026, selling an estimated $20.7M and leaving 251,922 shares worth $14.2M. The position accounts for 0.01% of the portfolio, ranked #1261.

Citigroup first reported a position in HAE in Q2 2013 and has held it in 52 quarters since. The position peaked at $45.6M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Citigroup held 251,922 shares of Haemonetics worth $14.2M as of Q1 2026.
  • Citigroup sold 317,251 Haemonetics shares in Q1 2026, an estimated $20.7M.
  • Haemonetics made up 0.01% of Citigroup's portfolio in Q1 2026, its #1261 holding.
  • Citigroup first reported a position in Haemonetics in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Haemonetics position peaked at $45.6M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.